The American Journal of Medicine
Volume 122, Issue 12 , Pages 1150.e1-1150.e9, December 2009

Comorbidities in Patients with Psoriasis

  • Alice B. Gottlieb, MD, PhD

      Affiliations

    • Tufts Medical Center, Boston, Mass
    • Corresponding Author InformationReprint requests should be addressed to Alice B. Gottlieb, MD, PhD, Tufts Medical Center, 800 Washington St, Box 114, Boston, MA 02111-1533
    • ,
  • Frank Dann, MD

      Affiliations

    • VA Medical Center, Long Beach, Calif

Abstract 

Psoriasis is a common chronic inflammatory disease that is associated with serious comorbidities, including psoriatic arthritis, reduced quality of life, depression, malignancy, and cardiovascular comorbidities. Patients with psoriasis have been shown to have an increased incidence of metabolic syndrome and cardiovascular disease compared with the general population. The chronic inflammatory nature of psoriasis has been suggested to be a contributing and potentially independent risk factor for the development of cardiovascular comorbidities. Understanding the interrelationship between these conditions is important for the management of psoriasis and the associated comorbidities. This review will focus on the range of comorbidities associated with psoriasis, with emphasis on cardiometabolic conditions and the aim of encouraging primary care physicians to screen psoriatic patients for cardiometabolic disorders and risk factors.

Keywords: Cardiovascular disease, Metabolic syndrome, Psoriasis, Psoriatic arthritis comorbidities

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Funding: Funding for writing assistance was provided by Amgen.

 Conflict of Interest: Almost all of Dr Gottlieb's consulting and speaking fees are paid to Tufts Medical Center. Dr Gottlieb is a member of the speakers bureau of Amgen Inc, and Wyeth Pharmaceuticals; has current consulting/advisory board agreements with Amgen Inc, Centocor, Inc, Wyeth Pharmaceuticals, Celgene Corp, Bristol-Myers Squibb Co, Beiersdorf, Inc, Abbott, Roche, TEVA, Actelion, UCB, Novo Nordisk, Almirall, Immune Control, Dermipsor Ltd., Incyte, Magen Biosciences, Stieffel, and Puretech; Tufts Medical Center has received research/educational grants from Centocor, Inc, Amgen Inc, Wyeth Pharmaceuticals, Immune Control, Celgene Corp, Pharmacare, Incyte, Novo Nordisk, Pfizer, and Abbott. Dr Dann is a former Amgen employee. He has participated on speakers bureaus for Amgen Inc and Wyeth Pharmaceuticals and has a consulting agreement with Amgen.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(09)00684-6

doi:10.1016/j.amjmed.2009.06.021

The American Journal of Medicine
Volume 122, Issue 12 , Pages 1150.e1-1150.e9, December 2009

Article Tools

* Image Usage & Resolution